PharmAla positions its GMP MDMA to supply new U.S. expanded-access pathway

PharmAla Biotech Holdings Inc. (MDMA) — PharmAla Biotech said the executive order's directive to establish access pathways for investigational psychedelics plays to its strengths, noting it already has GMP-grade LaNeo MDMA present in the U.S. and supplying programs including VA and Defense Health Agency channels.

The company said it operates a commercial MDMA supply operation through its Australian joint venture and is advancing its next-generation ALA-002 candidate. PharmAla framed itself as a ready supplier as U.S. expanded-access demand potentially grows.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.